(Q45861556)

17 December 2017

reason for preferred rank

title

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00771.X

24 December 2023

Long-term FEIBA prophylaxis does not prevent progression of existing joint disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694515

24 December 2023

author

Margaret W. Hilgartner

1

object named as

M W Hilgartner

1 reference

17 December 2017

author name string

A. Makipernaa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694515

24 December 2023

D. M. Dimichele

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12694515

24 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12694515

24 December 2023

publication date

1 May 2003

1 reference

17 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2516.2003.00771.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00771.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2516.2003.00771.x

24 December 2023

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00771.X

24 December 2023

1 reference

17 December 2017

volume

9

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

261-268

1 reference

17 December 2017

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00771.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00771.X

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00771.X

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00771.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00771.X

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00771.X

Methods to treat chronic haemophilic synovitis

24 December 2023

7

1 reference

https://api.crossref.org/works/10.1046/J.1365-2516.2003.00771.X

24 December 2023

Identifiers

1 reference

17 December 2017

1 reference

17 December 2017